<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136535</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER-L031</org_study_id>
    <nct_id>NCT04136535</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC</brief_title>
  <acronym>PCA</acronym>
  <official_title>A Multicenter, Randomized, Phase II Study of Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Advanced or Locally-advanced Osimertinib-resistant Non-squamous Non-small Cell Lung Cancer (ALTER-L031)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed&#xD;
      and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced&#xD;
      Osimertinib-resistant non-squamous non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin use 4 cycles,then&#xD;
      continue pem and anlotinib until PD&#xD;
&#xD;
      Pemetrexed and Carboplatin use 4 cycles,then continue pem until PD&#xD;
&#xD;
      TO see the different of PFS and OS and safety between the two group&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months</time_frame>
    <description>Progress free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed and Carboplatin with Anlotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed and Carboplatin without Anlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed and Carboplatin without Anlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed，500mg/m²，ivgtt ，d1，q3w</description>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
    <arm_group_label>Pemetrexed and Carboplatin without Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin，AUC 5.0，ivgtt，d1，q3w，</description>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
    <arm_group_label>Pemetrexed and Carboplatin without Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib ，12 mg，po，qd，d1-14，q3w；</description>
    <arm_group_label>Pemetrexed and Carboplatin with Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. 18 Years to 75 Years patients voluntarily participate in this study, signed and dated&#xD;
        informed consent with good compliance and follow-up; 2. Confirmed as locally advanced and /&#xD;
        or metastatic non-squamous non-small cell lung cancer (NSCLC) by cytology or histology, the&#xD;
        diagnosis should be completed at least 6 months after the end of chemotherapy if adjuvant&#xD;
        chemotherapy and / or neoadjuvant chemotherapy received (diagnosis based on sputum smear is&#xD;
        not accepted) ; 3. Presence of EGFR activating mutations and previously disease progression&#xD;
        to Osimertinib (previously treated with 1st / 2nd generation EGFR-TKI or not)； 4. At least&#xD;
        one target lesion that has accurate measurement by magnetic resonance imaging (MRI) or&#xD;
        computed tomography (CT) (conventional CT≥20 mm or spiral CT≥10 mm) in at least 1&#xD;
        direction; 5. Life expectancy is at least 3 months; 6. ECOG PS Scoring: 0~1 point; 8. The&#xD;
        main organs function are normally, the following criteria are met:&#xD;
&#xD;
        Blood routine examination criteria (no blood transfusion and blood products within 14 days,&#xD;
        no correction by G-CSF and other hematopoietic stimuli):&#xD;
&#xD;
        i) hemoglobin (HB) ≥90g/L ii) neutrophil absolute (ANC) ≥1.5×109/L iii) platelet (PLT)&#xD;
        ≥80×109/L Biochemical tests meet the following criteria i) total bilirubin (TBIL) ≤1.5&#xD;
        times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate&#xD;
        aminotransferase (AST)≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii)&#xD;
        serum creatinine (Cr) ≤1.25 ULN or creatinine clearance (CCr)≥45mL/min (Cockcroft-Gault&#xD;
        formula).&#xD;
&#xD;
        9.Female patients of childbearing age agree that contraceptive measures must be used within&#xD;
        the study period and within 8 weeks after the end of the study drug treatment. The serum or&#xD;
        urine test indicates unpregnancy within 7 days prior to the study. Male patients agree to&#xD;
        have contraceptive use during the study period and within 8 weeks after the end of the&#xD;
        study period or have had surgical sterilization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with small cell lung cancer (including small cell carcinoma and non-small&#xD;
             cell carcinoma mixed lung cancer) and lung adenosquamous carcinoma mixed with squamous&#xD;
             carcinoma;&#xD;
&#xD;
          2. Active brain metastases, cancerous meningitis, spinal cord compression, or imaging CT&#xD;
             or MRI screening for brain or pia mater disease (a patient with brain metastases who&#xD;
             have completed treatment and stable symptoms in 21 days before enrollment may be&#xD;
             enrolled, but should be confirmed by brain MRI, CT or venography evaluation as no&#xD;
             cerebral hemorrhage symptoms);&#xD;
&#xD;
          3. Imaging (CT or MRI) shows that the distance between tumor lesion and the large blood&#xD;
             vessel is ≤ 5 mm, or there is a central tumor that invades the local large blood&#xD;
             vessel and the distance between tumor and bronchial tree is ≤ 2 cm; or there is a&#xD;
             significant pulmonary cavity or necrotizing tumor;&#xD;
&#xD;
          4. Uncontrollable hypertension (systolic blood pressure ≥140 mmHg or diastolic blood&#xD;
             pressure ≥90 mmHg after optimal medical treatment);&#xD;
&#xD;
          5. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial&#xD;
             infarction above grade II, poorly controlled arrhythmias (including men with QTc&#xD;
             interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grades III to IV&#xD;
             Insufficient function, or cardiac color Doppler ultrasound examination indicates left&#xD;
             ventricular ejection fraction (LVEF) &lt;50%;&#xD;
&#xD;
          6. Abnormal blood coagulation (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds or&#xD;
             APTT &gt; 1.5 ULN), with bleeding tendency or undergoing thrombolytic or anticoagulant&#xD;
             therapy;&#xD;
&#xD;
          7. Urine routine test protein ≥++, and confirmed 24 hours urine protein&gt; 1.0 g;&#xD;
&#xD;
          8. There is currently a peripheral neuropathy of ≥CTCAE 2 degrees, except for trauma;&#xD;
&#xD;
          9. Respiratory syndrome (≥CTC AE grade 2 dyspnea), serous effusion (including pleural&#xD;
             effusion, ascites, pericardial effusion) requiring surgical treatment;&#xD;
&#xD;
         10. Long-term unhealed wounds or fractures;&#xD;
&#xD;
         11. Serious infection (≥CTC AE Level 2 infection) requiring systemic antibiotics;&#xD;
&#xD;
         12. decompensated diabetes or other ailments treated with high doses of glucocorticoids;&#xD;
&#xD;
         13. Active or chronic hepatitis C or/and hepatitis B infection;&#xD;
&#xD;
         14. Factors that have a significant impact on oral drug absorption, such as inability to&#xD;
             swallow, chronic diarrhea, and intestinal obstruction;&#xD;
&#xD;
         15. Patients have undergone major surgery within 4 weeks before enrollment or have severe&#xD;
             trauma, fracture and ulcer;&#xD;
&#xD;
         16. Severe weight loss (greater than 10%) within 6 weeks prior to enrollment;&#xD;
&#xD;
         17. Clinically significant hemoptysis (daily hemoptysis greater than 50ml) within 3 months&#xD;
             prior to enrollment; or significant clinically significant bleeding symptoms or&#xD;
             defined bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric&#xD;
             ulcer, baseline fecal occult blood ++ and above, or suffering from vasculitis;&#xD;
&#xD;
         18. Events of venous/ arterious thrombosis occurring within the first 12 months prior to&#xD;
             enrollment, such as cerebrovascular accidents (including transient ischemic attacks,&#xD;
             cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary&#xD;
             embolism;&#xD;
&#xD;
         19. Patients have contraindication to platinum drugs (Cisplatin/Carboplatin) and cytotoxic&#xD;
             drug (Pemetrexed);&#xD;
&#xD;
         20. Patients have anaphylactic reaction due to Anlotinib Hydrochloride or the excipient in&#xD;
             investigational drug.&#xD;
&#xD;
         21. Planned for systemic anti-tumor therapy during the study period or within 4 weeks&#xD;
             prior to enrollment, including cytotoxic therapy, signal transduction inhibitors,&#xD;
             immunotherapy (or use mitomycin C within 6 weeks prior to receiving investigational&#xD;
             drug). Radiation-rehabilitation radiotherapy (EF-RT) was performed within 4 weeks&#xD;
             before enrollment or limited-field radiotherapy was performed for planned tumor&#xD;
             lesions within 2 weeks before enrollment.&#xD;
&#xD;
         22. Patients with other situations which are not suitable for the study according to the&#xD;
             researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chang j hua, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chang J hua, PD</last_name>
    <phone>18017312689</phone>
    <email>changjianhua@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiang h wu, dorctor</last_name>
    <phone>13482888167</phone>
    <email>xhwu2011@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chang j hua, PD</last_name>
      <phone>18017312689</phone>
      <email>changjianhua@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.</citation>
    <PMID>27959700</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>primary care physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

